



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :

B01D 25/00, 63/08, 71/10

A1

(11) International Publication Number:

WO 93/08894

(43) International Publication Date:

13 May 1993 (13.05.93)

(21) International Application Number: PCT/US92/09164

(22) International Filing Date: 28 October 1992 (28.10.92)

(30) Priority data:

787,061

4 November 1991 (04.11.91) US

(71) Applicant: COULTER CORPORATION [US/US]; 600 West 20th Street, Hialeah, FL 33010 (US).

(72) Inventors: GLENN, Stephan, D. ; 15701 Huntridge Road, Davie, FL 33331 (US). BUTCHKO, Gregory ; 7485 Fairway Drive, Miami Lakes, FL 30014 (US). O'CONNELL, Edward ; 5500 S.W. 77th Ct., #315, Miami, FL 33155 (US). SMARIGA, Paulette ; 2165 N.E. 123rd Street, North Miami, FL 33181 (US).

(74) Agents: CASS, Myron, C. et al. ; Silverman, Cass & Singer, Ltd., 105 W. Adams Street, 27th Floor, Chicago, IL 60603 (US).

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).

Published


With international search report.

With amended claims.

(54) Title: PROCESS AND APPARATUS FOR REMOVAL OF DNA, VIRUSES AND ENDOTOXINS

(57) Abstract

A process for the removal of DNA, endotoxins and viruses from aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions comprises passing one of above solutions through a single filtration device with two sections containing coated filter membranes (34, 36) and absolute pore filters (32, 38, 62, 64, 66, 68). The filter device is capable of removing up to about 98 % of the endotoxins in addition to removing viruses with an efficiency of at least 4.6×10^5 and DNA to less than 10 picograms per 500 mg sample.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

PROCESS AND APPARATUS FOR REMOVAL OF DNA
VIRUSES AND ENDOTOXINS

RELATED APPLICATION

This application is a continuation-in-part of U.S.
5 Serial No. 07/546,011 filed June 29, 1990 and entitled
"PROCESS AND APPARATUS FOR REMOVAL OF DNA AND VIRUSES".

TECHNICAL FIELD

The present invention relates to a process for
removing DNA and viruses from physiological fluids and
10 medicant solution administered to humans and animals, and
an apparatus for performing said process. More
particularly, the invention is especially effective for
removing DNA, viruses and endotoxins from biological
pharmaceutical solutions and biological media, for
15 example, DNA, viruses and endotoxins from a monoclonal
antibody solution, buffer solutions or a solution of
bovine serum albumin.

BACKGROUND ART

One objective in the preparation of pharmaceutical
20 solutions, buffer solutions, life support solutions,
saline solutions and other such solutions which are to be
administered to animals and humans is that they be as
free as possible from substances which might cause an
adverse reaction in the host. While a goal of zero
25 contamination by substances such as DNA, viruses and
endotoxins is always sought, in actual practice very
minute amounts of such substances are sometimes present.
The Food and Drug Administration (FDA) has set standards
for such substances which cannot be exceeded.
30 Manufacturers, ever mindful that a batch of medicant may
be rejected if the level of such substances is too high,
continually seek new methods to ensure that their
products do not exceed FDA standards. Consequently, in
all phases of the manufacturing process, manufacturers
35 seek to ensure the purity of the reagents used in the
manufacture as well as the final product. Many of the

medicants and other products mentioned above are either sold as aqueous solutions or are manufactured in aqueous medium. Consequently, the manufacturers seek to ensure that the water they use is free of DNA, viruses and endotoxins.

One technology that such manufacturers often use is ultrafiltration. United States Patent Nos. 4,431,545 to Pall et al, 4,816,162 to Roskopf et al, and 4,420,398 to Castino, describe dual-module filtration to remove pathological and/or toxic substances from various fluids including water, blood and plasma. Patent No. 4,431,545 utilizes dual filters, one of which has a negative zeta potential and one of which has a positive zeta potential, to filter out positively and negatively charged particles. Neutral particles are removed in accordance with the pore size ratings of the filters which are 0.01 microns or larger as disclosed. Patent No. 4,816,162 describes an apparatus that removes immunoglobulins, albumin and lipoproteins from blood, blood plasma or serum, but does not describe the removal of DNA or viruses. The filter in this patent is designed for use in circulating and purifying blood during surgery. Patent No. 4,420,398 describes a filtration method for separating cell produced antiviral substances, including monoclonal antibodies, from the reaction "broth" in which they are produced. This patent does not indicate whether the resulting species are free of viruses, endotoxins and DNA which may cause a reaction within a patient.

It is known in the prior art that multiple filtration with a 0.04 micron absolute pore size filter will remove viruses of 0.075 micron size, but not smaller viruses. For example, filtration of calf serum containing MS 2 phage (0.024 micron) through 0.04 micron will not remove the virus. In those circumstances where virus can be removed, removal rate is typically 99.9 to 99.99% per filter pass. For example, using a 0.04 micron filter, applicants removed all detectable Reovirus (0.075

micron) from a sample containing 10^8 virus particles per milliliter sample. An article published in the April, 1990 issue of Genetic Engineering News (page 6) commented on the Food and Drug Administration's (FDA) increasing emphasis on viral removal protocols with regard to the preparation of biological pharmaceuticals and the efforts being made by filter manufacturers to achieve higher degrees of virus removal.

Another contaminant which can be present in biological pharmaceuticals such as monoclonal antibodies is DNA. It is generally felt in the industry that the FDA seeks to achieve a DNA level in monoclonal antibody preparations of less than 10 picograms of DNA per dose of monoclonal antibody.

Manufacturers of biological pharmaceutical such as monoclonal antibodies are required to establish Quality Assurance (QA) procedures to which verify that their products meet standards. In the procedures used to show compliance with the standards, it is necessary that the DNA in a sample be concentrated or solid phased (collected in solid form) from a solution of the biological pharmaceutical. It is known that DNA can be concentrated, solid phased or removed from solution by the use of diethylaminoethyl cellulose (DEAE) filter membranes. A manufacturer's literature (Schleicher & Schuell) indicates that DEAE filters will solid phase more than 90% of E. coli DNA from a solution containing 0.2 μg DNA/ml. In a more dilute solution containing 0.001 μg DNA (1 nanogram) more than 80% will be solid phased. The DEAE filters work by binding a protein such as DNA to the filter. However, a major limitation arises in the use of DEAE filters with some monoclonal antibody solutions. For example, it has been found that DNA measurements of monoclonal antibody containing buffer solution having components such as maltose can result in cause false high or low DNA values. In order to assure that the DNA assay values are accurate, these false

readings must be eliminated.

5 Lastly, in addition to viruses and DNA, endotoxins are important contaminating substances in biological pharmaceuticals. While some manufacturers offer column
10 packing materials which are useful in removing endotoxins from protein solutions such as solutions of monoclonal antibodies, such packing materials often result in low product yields after passage of the protein solution through the column. The DEAE filter membranes described
15 above have also been reported to remove endotoxins. However, we have not found the membranes to be effective in removing endotoxins from all sources. In some instances removal is high, whereas in others it is low. This variation is believed to be due to structural
20 variation of the endotoxins themselves in the various samples. The variations in the endotoxins are, in turn, believed dependent on the source of the endotoxin itself and on the chemical treatment it has been subjected to. Having done a careful study of the extant art, we have
developed a single filtration device capable of removing virus, DNA and at least some endotoxins to lower levels than previously achieved.

DISCLOSURE OF INVENTION

25 A single filtration device or apparatus containing DEAE coated filter membranes and absolute pore filters is provided in which the membranes and absolute pore filters are present in two sections of the filter device. The first section of the device is the DNA filter section comprising a first 0.2 micron filter, a first DEAE
30 filter, a second DEAE filter and a second 0.2 micron filter. The second section is the virus filter section comprising a first 0.1 micron filter, a second 0.1 micron filter, a first 0.04 micron filter, and a second 0.04 micron filter. The filter sections can be housed in a
35 single filter device or, alternatively, the sections can be housed in separate housings provided that in use, the housing containing the DNA filter section precedes the

housing containing the virus filter section and that the two are connected. In order to achieve higher levels of filtration than that afforded by a single device, multiple devices can be combined in series. The device
5 may be used on a large scale at point of manufacturing or packaging a pharmaceutical solution, or it can be used on a small scale at the point of administration to a patient. In either case, the DNA and viruses are removed by passing the pharmaceutical solution through the DNA
10 and virus filters by the use of either pressure to push the solution through the filter elements, as when administering to a patient, or vacuum to draw the solution through the filter elements as in some manufacturing procedures.

15 The apparatus embodying the invention will remove viruses, as modeled by type-C Xenotropic retrovirus, with an efficiency of at least 4.6×10^5 or approximately 99.995%, or 3×10^{10} bacteriophage (99.99999997%) ; remove DNA from levels of 10 $\mu\text{g}/\text{sample}$ to levels below 10
20 picograms per 500 mg sample of monoclonal antibody and preferably below 1 picogram per sample and will remove at least 97% of some bacterial endotoxins. Further, these filter units absorb less than 10% of the pharmaceutical or biological pharmaceutical, and most often 6% or less
25 of such pharmaceuticals, particularly monoclonal antibodies and bovine serum albumin.

In an alternative embodiment of the invention, the DEAE filter membranes are replaced by absolute pore
30 filters which have been coated with DEAE, QAE (quaternary aminoethyl salts), QAM (quaternary aminomethyl salts) and other like quaternary salts. For example, the first and second DEAE filter membranes 0.04 micron filters are coated with QAE or QAM.

Another alternative embodiment of the invention is
35 an improved apparatus wherein DEAE, QAE and QAM salts, and other like substances, are directly coated on or bonded to one or more of the 0.2, 0.1 and 0.04 micron

absolute pore filters. The resulting absolute pore filters thereby replace the DEAE cellulose filters.

BRIEF DESCRIPTION OF DRAWINGS

Fig. 1 is a perspective view of single unit of filter apparatus embodying the invention;

5 Fig. 2 is an exploded view of the apparatus shown in Fig. 1;

Fig. 3 is a perspective view of a multiple unit filter apparatus embodying the invention;

10 Fig. 4 is an exploded view of the apparatus shown in Fig. 3.

BEST MODE FOR CARRYING OUT THE INVENTION

Referring to Fig. 1, the invention is a filter device 12 comprising a two-piece filter housing part having a top part 14 with inlet port 18, a base part 16 with outlet port 20 and a series of internal elements (not shown) with said top part and base part being joined together in a leakproof manner; for example, by screwing the two parts together, by ball and socket attachment or other such means.

20 Figure 2 is an exploded view of the device of the invention. The device comprises the visible external members 14, 16, 18 and 20 as described above and internal elements, said internal elements being a first flat filter support 24 having a plurality of channels 26 extending through the thickness of the support; a first sealing member 28 extending a lateral distance inward from the inner wall of the filter housing; a first filter section 30 having filter elements 32, 34, 36 and 38 in sequential facial contact from one to the other throughout; a filter support 40 with a flat top face 42 in contact with the bottom face of filter element 38, a plurality of channels 26 extending through the thickness of the support and a plurality of rigid legs 44 at the outer edge of the bottom face of said support; a second flat filter support 46 having a plurality of channels 26
35 extending through the thickness of the support and whose

top face 48 is in contact with legs 44; a second sealing member 50; a second filter section 60 having filter elements 62, 64, 66 and 68 in sequential facial contact from one to the other throughout; a third flat filter support 70 having a plurality of channels 26 extending through the thickness of said support; and wherein the top to bottom face contact of the element is 28 to 24, 32 to 28, 34 to 32, 36 to 34, 38 to 36, 40 to 38, 50 to 46, 62 to 50, 64 to 62, 66 to 64, 80 to 66 and 70 to 68; and the top of face of element 24 is supported by the interior of top housing 14 and the bottom face of element 72 is supported by the interior of housing 16; and wherein sealing said interior elements by joining said top and base housing causes a pressure to be exerted on said sealing members 28 and 50 causing said sealing members to seal to the walls of said housing thereby preventing flow around filter sections 30 and 60, and forcing said flow to occur only through said filter sections.

Referring to Fig. 3, a second embodiment of the invention is a two section filter device 12 having a first DNA removal filter unit 4 and a second virus removal unit 6 joined by a connecting means 80.

Fig. 4 is an exploded view of the two unit filter device as shown in FIG. 3 comprising a first DNA removal filter unit having a top filter housing part 14 with inlet port 18 and a base filter housing part 16 with outlet port 20, and internal members flush to the interior walls and sequentially in facial contact with each other; said internal members being a first flat filter support 24 having a plurality of channels 26 extending through the thickness of the support; a sealing member 28 in contact with the inner side walls of said housing and extending a lateral distance inward from the inner wall; a DNA filter section 30 having filter elements 32, 34, 36 and 38; a second flat filter support 72 having a plurality of channels extending through the

thickness of the support; and a second virus removal filter unit 6 having a top filter housing part 15 with inlet port 19 and a base filter housing part 17 with outlet port 21 and internal members which are sequentially in facial contact with each other; said internal members being a first flat filter support 46 having a plurality of channels extending through the thickness of said support; a first sealing member 50 in contact with the inner side walls of said housing and extending a lateral distance inward from said inner wall; a virus filter section 60 having filter elements 62, 64, 66 and 68; and a filter support member 62 having a plurality of channels 26 extending through the thickness of said support; and a connecting member 80 joining said DNA filter unit 4 and said virus removal filter unit 6 by connecting outlet port 20 and inlet port 19; wherein the top to bottom face contact of the elements is 28 to 24, 32 to 28, 34 to 32, 36 to 34, 38 to 36, 72 to 38, 50 to 46, 62 to 50, 64 to 62, 66 to 64, 68 to 66, and 70 to 68; and top face of elements 24 and 46 is supported by the interior of their respective housings 14 and 15 and the bottom face of elements 70 and 72 is supported by the interior of their respective housings 16 and 17; and whereby enclosing said interior elements by joining respective top and base housings parts causes a pressure to be exerted on said sealing members thereby preventing flow around filter section 30 and 60, and forcing said flow to occur only through said respective filter sections; and said first DNA removal filter part and said second virus removal filter part being joined by connecting means 80 attached to parts 19 and 20.

The filter units as described above can be in any suitable size and shape possible, i.e., round, square or rectangular, subject only to limitation of the availability of size and shape of the filter material for filter sections 30 and 60. The filter units can be sized to handle commercially useful quantities of water for use

in the manufacture or preparation of buffer solutions, pharmaceuticals, pharmaceuticals solutions and the like. The filter can be used at any point in a manufacturing processes where a new aqueous material is added and is especially useful in removing DNA, virus and endotoxins in the packaging step at the end of the manufacturing process. In addition, the filter system of the present invention can be used in conjunction with a device for administering a physiological or a pharmaceutical solution to a patient; for example, the filter system can be built into or placed into a hypodermic syringe. In all instances of use, the solution being filtered passes through the DNA removal filter section and then passes through the virus filter section.

The filter elements of the filter apparatus described above are a combination of diethylaminoethyl cellulose and absolute pore filters. These filters, when used in the apparatus of this invention, will remove a ca. 0.1 micron type-C retrovirus with an efficiency of 4.6×10^5 or higher, remove DNA to level of 10 micrograms/ml to levels below 1 picogram/ml and will remove about 97% of some bacterial endotoxins. Alternately viewed, the device removes DNA from a level of 10 picograms/dose to levels below 1 picogram/dose. In addition, the filter elements of the present invention absorb 6% or less of proteins from the solution under treatment: for example, monoclonal antibody or bovine serum albumin solution. In the preferred embodiment of the invention elements 32 and 38 are 0.2 micron absolute pore filters; elements 34 and 36 are DEAE coated filters such as, for example, Schleicher & Schuell's NA45 filters; elements 62 and 64 are 0.1 micron absolute filters; and elements 66 and 68 are 0.04 micron absolute pore filters.

In the preferred embodiment of the invention, infectious virus particles of about 0.108 micron size can be removed with an efficiency of at least 99.99% per

passage through the filtration apparatus. Higher efficiencies can be obtained by using two or more of the filter apparatus in series.

5 In a process utilizing the apparatus of this invention, the water, aqueous buffer solutions and pharmaceutical solutions, including biological pharmaceutical solutions, have a pH in the range of 3 to 9. Further, these solutions have a specific salt content of less than 0.5 Molar, said specific salts being one or
10 more selected from the group consisting of the lithium, sodium, potassium or ammonium salts of the phosphate, chloride, bromide, iodide, sulfate and acetate anions. When utilizing the device of this invention, solutions are first passed through the DNA removal section prior to
15 passage through the virus removal section.

The following examples are given to illustrate the utility of the present invention and are not to be construed as limiting the scope of the invention.

Example 1. Virus Removal

20 The internal elements of the filter unit of the invention were assembled using eight filter element in the sequence 0.2 micron, DEAE, DEAE, 0.2 micron, 0.1 micron, 0.1 micron, 0.04 micron and 0.04 micron. The 0.2, 0.1 and 0.04 micron elements were absolute pore
25 filters, and the DEAE elements were NA 45 filters (Schleicher & Schuell). The units were sealed in autoclavable syringes and were autoclaved or gas sterilized using standard procedures. The sterilized syringes containing the filter elements were sent to
30 Microbiological Associates, Inc., Life Sciences Center, 9900 Blackwell Road, Rockville, Maryland 20850 for evaluation with monoclonal antibody solutions spiked with mouse xenotropic retrovirus of similar size to type C retrovirus (0.1 micron v 0.104 micron respectively).
35 Each syringe filter device was valuated against one sample of retrovirus spiked monoclonal antibody. By S+L-

-11-

assay, the samples contained 4.37×10^5 , 5.6×10^5 and 4.1×10^5 FFU/ml.

$$[\text{FFU/ml} = (\text{mean number of foci/dish} \times \frac{1}{\text{volume/dish}} \times \frac{1}{\text{dilution}})]$$

5 After passage of the test samples through the syringe filter units, the filtrates were re-analyzed in triplicate for retrovirus. No retrovirus found in any of the three monoclonal antibody filtrates. Antibody recovery was greater than 90%.

10 Example 2. Removal Of Bacteriophage By DNA/ Virus Removal Filters.

The maximum concentration of xenotropic retrovirus attainable is about 10^6 FFU/ml. In order to validate the DNA/Virus removal filters of this invention for higher virus particle removal efficiencies, bacteriophage T4 (approximately 0.1 micron) was chosen as a second model virus. The assay for bacteriophage T4 concentration was the formation of plaques (PFU) on a lawn of Escherichia coli B (ATCC 11303). The bacteriophage T4 was grown to maximum concentration (9.9×10^{10} PFU/ml) and the undiluted bacteriophage solution was divided into three aliquots. Each aliquot was filtered through a separate DNA/Virus removal filter device. The concentration of bacteriophage T4 in the filtrate was assayed by dilution and plating on dishes of E. coli. None of the three filtrates contained viable virus. The assay has an uncertainty of 3.3 FFU. These results indicate that the DNA/Virus removal filter device of the present invention is capable of reducing the concentration of an 0.1 micron bacteriophage by at least 3.0×10^{10} fold (99.99999997%). Similar results should be obtainable with viruses of similar size, approximately 0.1 micron, such as type C retrovirus. Type C retrovirus has been found to be a contaminant in the conditioned raw material for

15
20
25
30
35

monoclonal antibody pharmaceutical. To the inventors' knowledge, no single pass through any filter device as previously achieved this level of virus removal. Use of the filter device of the present invention should reduce the concentration of type C retrovirus in the conditioned raw material by at least 3×10^{10} fold. Thus, solutions containing nominal virus counts on the order of 10^7 should be able to be filtered to an undetectable virus level with a 1000 fold safety margin. In those cases, where the virus load of a solution is higher, over 10^7 , the solution can be filtered two or more times to obtain a solution having an undetectable virus level. Using two of the filter devices of the present invention in series would allow the removal of approximately 10^{17} - 10^{18} virus particles per ml $[(3 \times 10^{10}) \times (3 \times 10^{10}) / 1000 = 9 \times 10^{17}]$.

Example 3. DNA Removal From Spiked Antibody Solutions

Monoclonal antibody solutions containing 400 mg of antibody each and DNA were filtered through the DNA/virus removal filter unit of the invention. DNA analysis before and after filtration showed 727 pg and 442 pg of DNA per sample before filtration; and 5pg and 1pg DNA, respectively, after filtration (99.3% and 99.8% removal).

Example 4. DNA Removal From Commercial Antibody Solutions

Analysis of commercial monoclonal antibody solutions indicated that there is significant DNA contamination. The analysis was performed using an assay kit from FMC Bio Products, Rockland, Maine (FMC assay) for the detection of DNA solid-phased on Nylon 66 membranes. Five lots of DNA containing monoclonal antibody solution were analyzed for DNA before and after filtration through a filter apparatus of the invention: All filtered solutions had less than 10 picograms of DNA per dose of antibody and two of the five showed less than 1 picogram

per dose. The results are shown in Table 1.

Table 1 SUMMARY of DNA REMOVAL from antibody products

Product No.	Mean DNA		Concentration
	Before Filtration	After	
<u>Filtration</u>			
	pg DNA/mg Mab	pg DNA/dose	pg DNA/dose
1	0.65	260	2.6
2	0.30	120	0.4
3	0.34	3.4	2.6
4	0.13	1.3	3.1
5	0.13	140	0

Example 5. DNA Removal Validation

In order to validate DNA removal for commercial purposes, the DNA/Virus removal filters were challenged with 500 mg samples of a pharmaceutical grade monoclonal antibody (B1) in buffer spiked with 100 micrograms of hybridoma produced DNA. The DNA used in the validation was purified from the same cell culture medium used to produce monoclonal antibodies and was as similar as possible to the DNA actually encountered in the production of the antibody. Three antibody solutions were spiked with the DNA. Two unspiked antibody solutions, two buffer (only) solutions without DNA and two buffer (only) solutions spiked with 100 micrograms of DNA were used as controls. The actual level in the spiked solutions was determined by means of a fluorescent DNA assay technique. The spiked antibody solutions were found to have actual DNA levels of 81, 92 and 74 micrograms per sample. The spiked buffer solutions were found to have actual DNA levels of 89 and 96 micrograms per sample. All solutions

samples were equal volume.

Each of the test solutions (9 solutions total) was filtered through a separate 25mm DNA/Virus removal filter apparatus. The residual DNA in each filtrate was concentrated, solid phased and quantified in duplicate using standard FMC DNA assay techniques. The quantity of DNA in each assay was determined from a standard curve of purified hybridoma DNA run in the same assay. For the standard curve, the color intensities of the sample bands, measured by the instrument's reflection densitometer, are measured as peak heights in centimeters. The standard curve data is linearly transformed by a log-logit transformation where the peak heights are converted to a logit (relative to a standard that will give maximum color development and a blank) versus the log of the picograms of DNA standard added. Test samples were then interpolated from the standard curve of DNA to color intensity. The results are given in Table 2 and indicate that a single pass through the DNA/Virus removal filter is capable of reducing the DNA levels by about 10^7 fold to approximately 10 picograms DNA per 500 mg of monoclonal antibody (mean = 12.3 pg DNA/500mg antibody). The mean value for an equal volume of unspiked buffer (only) is 6.2 pg. Therefore, the mean net DNA detected in the filtered, spiked antibody solution is 6.1 pg DNA/500 mg antibody.

Table 2

Sample	DNA Spike	DNA Detected in sample after DNA spiking	% Recovery of protein concentra- tion (Lowry)	Mean total DNA detected	
				Mean after filtration	
35	B1 500 mg	100 ug	81 ug	98.9%	16.5 pg
	B1 500 mg	100 ug	92 ug	98.0%	8.6 pg 12.3 pg
	B1 500 mg	100 ug	74 ug	96.7%	11.7 pg

	B1 500 mg	0	0	96.3%	3.3 pg	
	B1 500 mg	0	0	92.8%	3.2, pg	3.2 pg
	Buffer	100 ug	89 ug	N/A	16.9 pg	
	Buffer	100 ug	96 ug	N/A	3.3 pg	10.1 pg
5	Buffer	0	0	N/A	9.8 pg	
	Buffer	0	0	N/A	2.6 pg	6.2 pg

* total DNA in 500 mg sample of monoclonal antibody (mean observation of samples assayed in duplicate.)

10 Example 6. Endotoxin Removal.

A 100ml solution of 50mg/ml bovine serum albumin in 10% maltose-phosphate buffer solution contaminated with DNA and an endotoxin was filtered through a 47mm DNA/Virus removal filtration device. The starting solution contained 248 pg/ml DNA and 1966 endotoxin units/ml (EU/ml)/

First, middle and end 20ml portions of filtrate were collected and analyzed. No DNA was detected in any analyzed portion of filtrate. Endotoxin levels were: first= 30.72 EU/ml, middle= 30.72 EU/ml and last= 61.44 EU/ml. Endotoxin removal in the end sample was 96.9%. Solution recovery was 95% (95 ml) with no change in protein concentration.

CONTINUATION-IN-PART DISCLOSURE

25 BACKGROUND ART

Endotoxins are undesirable contaminants in parenteral drugs which can cause fever or a toxic reaction in the drug host. The upper limit for endotoxins in parenteral drugs generally acceptable to the U.S. Food and Drug Administration (FDA) is 5 EU/kg body weight/hour infusion. A manufacturer's release

criteria for parenteral drugs such as monoclonal antibodies, generally includes a specification for the maximum allowable endotoxin concentration. Production lots of parenteral drugs that fail to meet the specification release criteria must either be further processed to reduce the endotoxin concentration or be scrapped.

Column chromatography procedures for the removal of endotoxins have been described by M.D. Hollenberg et al., Can. J. Physiol Pharmacol., 59: 890-892 (1981); A.C. Issekutz, J. Immunological Methods, 61: 275-281 (1983); and in Technology Reports, December, 1984, pp 1035-1038. Column chromatography, however, entails considerable expense in equipment, chromatographic materials and waste disposal. Often it also results in a reduction in net product yield, thus increasing product cost. The invention described herein uses filter membranes, absolute pore filters and/or coated absolute pore filters to reduce the endotoxin level in aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions.

DISCLOSURE OF INVENTION

A single filtration device or apparatus containing DEAE coated filter membranes and absolute pore filters is provided which can remove up to 98% of the endotoxins present in aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions. The filter membranes and absolute pore filters provided by the invention are present in two sections of the device. The two sections of the device may be present in a single housing or may be in separate housings. The first section of the device is the DNA/endotoxin removal section and the second section is the virus/endotoxin removal section. In an alternate embodiment of the device, the filter membranes are removed and replaced by at least one absolute pore filter coated with DEAE, QAM or QAE salts and the like

-17-

substances, or mixture thereof. In yet another embodiment, the filter membranes are removed and at least one of the remaining absolute pore filters is coated with DEAE, QAM or QAE salts and the like substances, or
5 mixture thereof.

DETAILED DESCRIPTION OF THE INVENTION

The invention describes a process for the removal of DNA, endotoxins and viruses from aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous
10 biological pharmaceutical solutions by passing such solutions through a first DNA/endotoxin filter section and a second virus/endotoxin filter section, wherein the DNA, viruses and endotoxins are substantially removed, and collecting the aqueous buffer solutions, aqueous
15 pharmaceutical solutions or aqueous biological pharmaceutical solutions. The filter device comprises a first DNA/endotoxin filter section having:

(I) (A) (i) a first absolute pore filter;
(ii) a first and second filter selected
20 from one of the group of (a) a DEAE cellulose filter membrane and (b) an absolute pore filter coated with at least one of the group consisting of diethylaminoethyl (DEAE) salts, quaternary aminoethyl salts and quaternary aminomethyl salts and the like; and
25 (iii) a second absolute pore filter; or
(B) plurality of absolute pore filters at least one of which is coated with at least one selected from the group consisting of diethylaminoethyl (DEAE) salts, quaternary aminoethyl salts, quaternary
30 aminomethyl salts and the like; and

(II) a second virus filter section comprising absolute pore filters of a smaller diameter than the absolute pore filters or coated absolute pore filters in the DNA filter section

35 Samples from several lots of monoclonal antibody preparations were filtered through the filter device. The endotoxin concentration (endotoxin units ,EU) of the

sample solutions was measured by the Limulus Amebocyte Lysate (LAL) assay. The Associates of Cape Cod LAL (Cape Cod, Massachusetts) assay was used which has a maximum sensitivity of 0.06 EU/ml. The endotoxin standard had a stated activity of 10 EU/ng. Endotoxin endogenous to the purified monoclonal antibody products was used without spiking with purified endotoxin material. The LAL assay for bacterial endotoxins is described in the United States Pharmacopeia, USP XXII <85>.

Table 3. Reduction in concentration of LAL quantified endotoxin by filtration of monoclonal antibody products* through the DNA/Endotoxin/Virus filter device.

Lot or Exp. No.	Volume Filtered	Filter Size	Concentrations		
			mAb	Endotoxin EU/mg.	
				Before	After
	ml	mm2	mg/ml	Filtration	Filtration
1787-84A	10	25	5	0.10	≤0.01
1825-1A	50	25	20	0.77	0.01
1825-1B	50	25	20	0.77	≤0.01
1825-1C	50	25	20	0.77	0.77
5309001	30	25	7.12	8.63	0.33
5061002	568	90	5.01	24.35	0.77
5190002	91	90	20.74	0.09	0.01
5011001	80	90	53.08	0.02	0.01
5321007	60	90	42.90	0.04	0.01
5351001	63	90	21.64	0.02	0.01

* Monoclonal antibody products were tested by LAL assay for endotoxin concentration before and after treatment with the DNA/Endotoxin/Virus removal filter device.

The results in Table 3 illustrate that the endogenous endotoxin concentrations in the pharmaceutical grade monoclonal antibody preparations can be reduced by the DNA/Endotoxin/Virus removal filter device embodying the invention. The filter device reduced the

endotoxin concentration in these products by up to 98%. The observed reduction in endotoxin level of these monoclonal antibody products is sufficient to allow administration of these products at higher doses and/or greater infusion rates with reduced risk to the patient receiving the drug.

Example 7. Endotoxin Removal After Passage
Through The Filter Device.

The data presented in Table 1 indicates that lots of antibody product which could not be used can be salvaged by filtering through the DNA/Endotoxin/Virus filter device of the invention. For example, Lot 5071002 is a pharmaceutical grade monoclonal antibody which was not acceptable for its intended parenteral use because its endotoxin concentration of 24.35 E.U./mg was too high to allow infusion of the desired dosage in a reasonable time (product specification is 5 E.U./mg). The standard cost value of this product was \$50,000 which would have been lost if the product had been scrapped. However, after filtration through the DNA/Endotoxin/Virus filter device, the endotoxin concentration was reduced to an acceptable 0.77 E.U./mg.

Example 8. Evaluation of Endotoxin Removal After
Passage Through the First and Second
Sections of the Filter Device.

The data presented in Table 3 and Example 7 indicated the total amount of endotoxin removed after passage through the filter device of the invention. In this example, the amount of endotoxin removed by each filter section was measured. The results indicate that both sections are effective in removing endotoxins from the sample.

A 30 mg/mL sample of a 7.12 mg/mL solution of monoclonal antibody Lot Number 5309001 was passed through a 47mm diameter filter device. The DNA/ endotoxin removal

section contained two 0.2 micron filter membranes and two NA45 filter (Schleicher & Schuell). The virus/endotoxin section contained two 0.1 and two 0.04 micron filters assembled as described above. Endotoxin levels in the sample were measured before filtering, after passage through the DNA/endotoxin section but not the virus/endotoxin section, and after passage through both the DNA/endotoxin section and the virus/endotoxin section. Test results were:

10	<u>Sample Test</u>	<u>Endotoxin Level</u>
	Before Filtration	8.6 EU/mg antibody
	Between Sections	0.6 EU/mg antibody
	After Both Sections	0.3 EU/mg antibody

The analyses show that 93% of the endotoxins were removed by passage through the DNA/endotoxin section and 96.5% (an additional 3.5% of endotoxin, 50% of residual endotoxin) were removed by passage through both filter sections.

Example 9. Removal of Virus Particles.

The results obtained in Example 2 showed that this DNA/Endotoxin/Virus removal filter device can reduce the concentration of the bacteriophage T4 in a sample by at least a factor of 3×10^{10} . This example represents an additional experiment to determine whether the virus in the original experiment was inactivated or fragmented, and whether the inactivated virus or subunits thereof passed through the filter device.

The bacteriophage T4 was grown to a concentration of 5×10^{10} plaque forming units/ml. The bacteriophage suspension was then filtered through a DNA/Endotoxin/Virus removal filter device, the filtrate pelleted by ultracentrifugation and examined by transmission electron microscopy for T4 bacteriophage and T4 bacteriophage subunits. Neither T4 bacteriophage nor T4 subunits were observed. Based on the number of negative grids observed, the concentration of particles

in the filtrate was less than 1.73×10^5 /mi. This result indicates that at least 99.9997% of the virus particles or subunits were removed from the test solution suspension.

5 We Claim:

1. A process for the removal of DNA, endotoxins and viruses from aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions comprising, passing one of said aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions through a first DNA/endotoxin filter section and a second virus/endotoxin filter section, wherein said DNA, viruses and endotoxins are substantially removed; and collecting said aqueous buffer solutions, aqueous pharmaceutical solutions or aqueous biological pharmaceutical solutions;
- (I) said first DNA/endotoxin filter section having:
- (A) (i) a first absolute pore filter,
- (ii) a first and second filter selected from one of the group consisting (a) a DEAE cellulose filter membrane and (b) an absolute pore filter coated with at least one of the group consisting of diethylaminoethyl salts, quaternary aminoethyl salts and quaternary aminomethyl salts, and
- (iii) a second absolute pore filter; or
- (B) plurality of absolute pore filters at least one of which is coated with at least one selected from the group consisting of dimethylaminoethyl salts, quaternary aminoethyl salts, quaternary aminomethyl salts and the like; and
- (II) said second virus/endotoxin filter section having absolute pore filters of a smaller diameter than the absolute pore filters or coated absolute pore filters in the DNA filter section
2. The process in accordance with claim 1 wherein the yield of pharmaceuticals, including biological pharmaceuticals, in the filtered solutions is 90% or higher compared to the starting solution.
3. The process in accordance with claim 1 wherein the virus removal is 99.9999997% or higher when the virus is 0.100 microns or larger, and the yield of

pharmaceutical or biological pharmaceutical in the filtered solution of same is 90% or higher compared to the starting solution.

4. The process in accordance with claim 1 wherein said DNA in the filtered solutions is preferably less than 10 picograms per 100 ml of solution.

5. The process in accordance with claim 4 wherein said DNA in the filtered solutions is less than 1 picogram.

6. The process in accordance with claim 1 wherein said endotoxin removal is up to about 98% compared to the starting solution.

7. The process in accordance with claim 1 wherein the aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions have a pH in the range of 3 to 9.

8. The process in accordance with claim 1 wherein the aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions each have a specific salt content of less than 0.5 Molar, said specific salt being one or more selected from the group consisting of the lithium, sodium, potassium and ammonium salts of the phosphate, chloride, bromide, iodide, sulfate, and acetate anions.

9. A process for the removal of DNA, viruses and endotoxins from aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions, comprising passing either one of the solutions through a first DNA/endotoxin filter section and a second virus/endotoxin filter section to obtain a filtered aqueous pharmaceutical solution or a filtered aqueous biological pharmaceutical solution having substantially reduced DNA, virus and endotoxin levels, said solutions passing through:

(a) a first 0.2 micron absolute pore filter, a first diethylaminoethyl cellulose filter, a second diethylaminoethyl cellulose filter and a second 0.2

micron absolute pore filter in the first DNA filter section, and

5 (b) a first 0.1 micron absolute pore filter, a second 0.1 micron absolute pore filter, a first 0.04 micron absolute pore filter and a second 0.04 micron absolute pore filter;
and collecting the filtered solutions.

10 10. A process in accordance with claim 9 wherein the yield of the pharmaceutical, including biological pharmaceutical, in the filtered solution is 90% or higher.

15 11. A process in accordance with claim 9 wherein the virus removal is 99.9999997% (3×10^{10}) or higher when the virus is 0.100 microns or larger, and the yield of the pharmaceutical or biological pharmaceutical in the filtered solution is 90% or higher.

20 12. A process in accordance with claim 9 wherein the DNA in the filtered pharmaceutical or biological pharmaceutical solution is preferably reduced to less than 10 picograms.

25 13. The process in accordance with claim 12 wherein the DNA in the filtered pharmaceutical or biological pharmaceutical solution is reduced to less than 1 picogram.

30 14. The process in accordance with claim 9 wherein said endotoxin removal is up to about 98% compared to the starting solution.

35 15. A process in accordance with claim 9 wherein the pharmaceutical solution or biological pharmaceutical solution has a pH in the range of 6 to 8.

16. A process in accordance with claim 9 wherein the pharmaceutical or biological pharmaceutical has a specific salt content, excluding salts of pharmaceuticals or biological pharmaceuticals, of less than 0.5 Molar, said specific salts being at least one selected from the group consisting the lithium, sodium potassium and ammonium salts of the phosphate, chloride, bromide,

iodide, sulfate and acetate anions.

17. A process in accordance with claims 1 or 9
wherein in said aqueous buffer solutions, aqueous
pharmaceutical solutions and aqueous biological
5 pharmaceutical solutions are passed through said
DNA/endotoxin filter and said virus/endotoxin filter by a
vacuum means or a pressure means.

18. An improved device for the removal of DNA,
endotoxins and viruses from aqueous buffer solutions,
10 aqueous pharmaceutical solutions and aqueous biological
pharmaceutical solutions, said device having a housing
with suitable inlet/outlet means, internal gaskets and
filter supports, and internal filters wherein the
improvement comprises a first DNA/endotoxin filter
15 section having, from inflow to outflow, a first 0.2
micron filter, a first diethylaminoethyl cellulose
filter, a second diethylaminoethyl cellulose filter and a
second 0.2 micron filter, the filters having face-to-face
contact, and a second virus/endotoxin filter section
20 having, from inflow to outflow, a first 0.1 micron
filter, a second 0.1 micron filter, a first 0.04 micron
filter and a second 0.04 micron filter, said filters
having face-to-face contact.

19. An improved device in accordance with claim 18
25 wherein said 0.2, 0.1 and 0.04 filters are absolute pore
filters.

20. The improved device in accordance with claim 18
wherein said device is preferably capable of removing DNA
to a level of less than 10 picograms.

21. The improved device in accordance with claim 20
30 wherein said device is capable of removing DNA to a level
of less than 1 picogram.

22. The improved device of claim 18 wherein said
device is capable of removing 99.9999997% (3×10^{10}) of
35 virus when the virus is 0.100 microns or larger.

23. The improved device of claim 18 wherein said
device is capable of removing up to about 98% of

endotoxins present in the starting solution.

24. The improved device of claim 18 wherein the device gives a yield of pharmaceutical or biological pharmaceutical in the filtered solution of 90% or higher compared to the unfiltered solution.

25. The improved device of claim 18 where the solution to be filtered is passed through said device by pressure or vacuum means.

26. The improved device of claim 18 wherein said device is a means of administration of said aqueous buffer solution, aqueous pharmaceutical solution or said aqueous biological pharmaceutical solution to a patient which means contains said DNA/endotoxin and virus/endotoxin filter sections.

27. The improved device of claim 18 wherein said device is a syringe filtration apparatus containing said DNA/endotoxin and virus/endotoxin removal filters.

28. The improved device according to claim 18 wherein the DEAE functional groups, QAE functional groups, QAM functional groups or other quaternary amine functional groups are bonded directly to one or more of the 0.2, 0.1 and 0.04 micron absolute pore size filters thereby replacing the DEAE cellulose filter.

29. An improved device for the removal of DNA, endotoxins and viruses from aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions, said device having a housing with suitable inlet/outlet means, internal gaskets and filter supports, and internal filters wherein the improvement comprises a first DNA filter section having, from inflow to outflow, a first 0.2 micron filter, a second 0.2 micron filter, the filters having face-to-face contact; and a second virus filter section having, from inflow to outflow, a first 0.1 micron filter, a second 0.1 micron filter, a first 0.04 micron filter and a second 0.04 micron filter, said filters having face-to-face contact; wherein at least one of the absolute pore

filters is coated with at least one of the group consisting of DEAE, QAE, QAM and other quaternary ammonium salts.

5 30. A device for removing DNA, endotoxins and
pharmaceutical solutions and aqueous biological
pharmaceutical solutions comprising, a housing having
inlet and outlet means for such solutions, a stacked
10 assembly of filter sections and internal gasketing and
support means for said filter sections, said assembly
including a DNA filter section and a virus filter section
constructed and arranged to substantially remove DNA,
virus and endotoxins from such solution passed
15 therethrough, and means for collecting said solutions
after such removal of DNA, endotoxins and viruses.

31. The device according to claim 27 in which said
DNA filter section has

- (i) a first absolute pore filter,
- (ii) a first and second filter selected from one of
20 (a) a DEAE cellulose filter membrane and (b) an absolute
pore filter coated with at least one of diethylaminoethyl
salts, quaternary aminoethyl salts and quaternary
aminomethyl salts, and
- (iii) a second absolute pore filter; and said virus
25 filter section has absolute pore filters of smaller pore
diameter than the absolute pore filters in the DNA filter
section.

AMENDED CLAIMS

[received by the International Bureau on 15 March 1993 (15.03.93)
original claims 6,14,23 and 28-31 deleted; original claims 1,4,
5,10-13,15,18-20,22 and 24 amended; remaining claims
unchanged; claims renumbered 1-24 (5 pages)]

1. A process for the removal of DNA, about 98% of endotoxins and viruses from aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions comprising, passing one of said aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions through a first DNA/endotoxin filter section and a second virus/endotoxin filter section, wherein said DNA, viruses and endotoxins are substantially removed; and collecting said aqueous buffer solutions, aqueous pharmaceutical solutions or aqueous biological pharmaceutical solutions;

(I) said first DNA/endotoxin filter section having:

(A) (i) a first absolute pore filter,

(ii) a first and second filter selected from one of the group consisting (a) a DEAE cellulose filter membrane and (b) an absolute pore filter coated with at least one of the group consisting of diethylaminoethyl salts, quaternary aminoethyl salts and quaternary aminomethyl salts, and

(iii) a second absolute pore filter; or

(B) plurality of absolute pore filters at least one of which is coated with at least one selected from the group consisting of dimethylaminoethyl salts, quaternary aminoethyl salts and quaternary aminomethyl salts; and

(II) said second virus/endotoxin filter section having absolute pore filters of a smaller diameter than the absolute pore filters or coated absolute pore filters in the DNA/endotoxin filter section

2. The process in accordance with claim 1 wherein the yield of pharmaceuticals, including biological pharmaceuticals, in the filtered solutions is 90% or higher compared to the starting solution.

3. The process in accordance with claim 1 wherein the virus removal is 99.9999997% or higher when the virus is 0.100 microns or larger, and the yield of pharmaceutical or biological pharmaceutical in the

filtered solution of same is 90% or higher compared to the starting solution.

4. The process in accordance with claim 1 wherein said DNA in the filtered solutions is less than 10 picograms per 100 ml of solution.

5. The process in accordance with claim 4 wherein said DNA in the filtered solutions is less than 1 picogram per 100 ml of solution.

6. The process in accordance with claim 1 wherein the aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions have a pH in the range of 3 to 9.

7. The process in accordance with claim 1 wherein the aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions each have a specific salt content of less than 0.5 Molar, said specific salt being one or more selected from the group consisting of the lithium, sodium, potassium and ammonium salts of the phosphate, chloride, bromide, iodide, sulfate, and acetate anions.

8. A process for the removal of DNA, viruses and about 98% of endotoxins from aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions, said process comprising passing either one of the solutions through a first DNA/endotoxin filter section and a second virus/endotoxin filter section to obtain a filtered aqueous pharmaceutical solution or a filtered aqueous biological pharmaceutical solution having substantially reduced DNA, virus and endotoxin levels, said solutions passing through:

(a) a first 0.2 micron absolute pore filter, a first diethylaminoethyl cellulose filter, a second diethylaminoethyl cellulose filter and a second 0.2 micron absolute pore filter in the first DNA/endotoxin filter section, and

(b) a first 0.1 micron absolute pore filter, a second 0.1 micron absolute pore filter, a first 0.04 micron absolute pore filter and a second 0.04 micron absolute

pore filter in the virus/endotoxin filter section; and collecting the filtered solutions.

9. A process in accordance with claim 8 wherein the yield of the pharmaceutical, including biological pharmaceutical, in the filtered solution is 90% or higher.

10. A process in accordance with claim 8 wherein the virus removal is 99.9999997% or higher when the virus is 0.100 microns or larger, and the yield of the pharmaceutical or biological pharmaceutical in the filtered solution is 90% or higher.

11. A process in accordance with claim 8 wherein the DNA in the filtered pharmaceutical or biological pharmaceutical solution is preferably reduced to less than 10 picograms per 100 ml of solution.

12. The process in accordance with claim 11 wherein the DNA in the filtered pharmaceutical or biological pharmaceutical solution is reduced to less than 1 picogram per 100 ml of solution.

13. A process in accordance with claim 8 wherein the pharmaceutical solution or biological pharmaceutical solution has a pH in the range of 6 to 8.

14. A process in accordance with claim 8 wherein the pharmaceutical or biological pharmaceutical has a specific salt content, excluding salts of pharmaceuticals or biological pharmaceuticals, of less than 0.5 Molar, said specific salts being at least one selected from the group consisting the lithium, sodium potassium and ammonium salts of the phosphate, chloride, bromide, iodide, sulfate and acetate anions.

15. A process in accordance with claims 1 or 8 wherein said aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions are passed through said DNA/endotoxin filter and said virus/endotoxin filter by a vacuum means or a pressure means.

16. An improved device for the removal of DNA, about 98% of endotoxins and viruses from aqueous buffer

solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions, said device having a housing with suitable inlet/outlet means, internal gaskets and filter supports, and internal filters wherein the improvement comprises:

(a) a first DNA/endotoxin filter section having, from inflow to outflow, a first 0.2 micron filter and a second 0.2 micron filter, the filters having face-to-face contact;

(b) and a second virus/endotoxin filter section having, from inflow to outflow, a first 0.1 micron filter, a second 0.1 micron filter, a first 0.04 micron filter and a second 0.04 micron filter, said filters having face-to-face contact; and

(c) DEAE functional groups, QAE functional groups, QAM functional groups and other quaternary amine functional groups bonded directly to one or more of the 0.2, 0.1 and 0.04 micron filters.

17. An improved device in accordance with claim 16 wherein said 0.2, 0.1 and 0.04 filters are absolute pore filters.

18. The improved device in accordance with claim 16 wherein said device is preferably capable of removing DNA to a level of less than 10 picograms per 100 ml of solution.

19. The improved device in accordance with claim 18 wherein said device is capable of removing DNA to a level of less than 1 picogram per 100 ml of solution.

20. The improved device of claim 16 wherein said device is capable of removing 99.9999997% of virus when the virus is 0.100 microns or larger.



21. The improved device of claim 16 wherein the device gives a yield of pharmaceutical or biological pharmaceutical in the filtered solution of 90% or higher compared to the unfiltered solution.



22. The improved device of claim 16 where the solution to be filtered is passed through said device by pressure or vacuum means.

23. The improved device of claim 16 wherein said device is a means of administration of said aqueous buffer solution, aqueous pharmaceutical solution or said aqueous biological pharmaceutical solution to a patient which means contains said DNA/endotoxin and virus/endotoxin filter sections.

24. The improved device of claim 16 wherein said device is a syringe filtration apparatus containing said DNA/endotoxin and virus/endotoxin removal filters.

1/2





INTERNATIO SEARCH REPORT

PCT/US92/09164

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : B01D 25/00; B01D 63/08; B01D 71/10

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 210/507,508; 424/89

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

none

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A, 4,935,142 (STERNBERG) 19 JUNE 1990 See entire document	30
Y	US,A, 4,431,545 (PALL ET AL) 14 FEBRUARY 1984 See entire document	30
X,P Y,P	US,A, 5,076,933F (GLENN ET AL) 31 DECEMBER 1991 See entire document	9-13,15-22,24- 27,29 1-5,7-8,30-31

<input type="checkbox"/> Further documents are listed in the continuation of Box C.	<input type="checkbox"/> See patent family annex.
<p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be part of particular relevance</p> <p>*E* earlier document published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p>	<p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>*G* document member of the same patent family</p>
Date of the actual completion of the international search 07 DECEMBER 1992	Date of mailing of the international search report 15 JAN 1993
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer M SUN UK KIM NGUYEN NGOC-HO TELEPHONE No. (703) 308-2350

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/09164

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

210/641,651,655,321.64,335,446,500.29; 210/506; 422/1,101; 435/311; 935/19